Brandi Davis-Dusenbery Seven Bridges

Brandi Davis-Dusenbery has been appointed CEO at Seven Bridges

There’s changeover at the top for biomedical data analysis company Seven Bridges this week, with the announcement that Brandi Davis-Dusenbery will be taking over the role of CEO.

Formerly Senior VP of Science and Product, Brandi takes over from Deniz Kural as he takes up the reins of Executive Chairman of the Board of Directors. In her previous role she guided the creation of the Cancer Genomics Cloud, an NCI pilot that now supports the analytic needs of about 1,500 researchers investigating petabytes of genomic data collected in The Cancer Genome Atlas (TCGA).

“I came to Seven Bridges in order to help develop new science and technology to improve health care around the world,” said Brandi.  “I’m privileged to accelerate this work with our expanded leadership team, which shares a vision for making precision medicine a reality for research organizations worldwide.”

“Brandi is the perfect person to lead Seven Bridges through our next phase of innovation and growth,” said James Sietstra, president of Seven Bridges. “She has both the deep science background and operational experience to drive our mission of bringing the Seven Bridges Platform to commercial R&D enterprises and ambitious precision medicine projects around the globe.” 

As part of continued product growth and development, the company have also launched a new Scientific Advisory Board, designed to “formalise relationships with leading global experts in genomic medicine, bioinformatics and cancer research.” 

Among the inaugural members are Jan Korbel of the European Molecular Biology Laboratory, Heng Li of the Broad Institute, and Gholson Lyon of Cold Spring Harbour Laboratory. 

“As we continue to build on Seven Bridges’ vision to connect the world’s biomedical data for better research and health, input from leaders in the fields of genetics, bioinformatics and cancer research will prove invaluable to our efforts,” explained Brandi.

“We are honored that these respected experts have agreed to participate in our SAB and look forward to working with them to constantly advance the state of the art in data analysis for our large-scale pharmaceutical and government clients.”